SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-238295
Filing Date
2023-09-20
Accepted
2023-09-20 11:23:58
Documents
14
Period of Report
2023-09-20
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d509876d8k.htm   iXBRL 8-K 26872
2 EX-99.1 d509876dex991.htm EX-99.1 19002
6 GRAPHIC g509876g26m08.jpg GRAPHIC 38508
  Complete submission text file 0001193125-23-238295.txt   225597

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikt-20230920.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20230920_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20230920_pre.xml EX-101.PRE 11712
8 EXTRACTED XBRL INSTANCE DOCUMENT d509876d8k_htm.xml XML 3469
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 263407249 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 231265746
SIC: 2836 Biological Products, (No Diagnostic Substances)